Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

✍ Scribed by Gustavo Ismael; Roberto Hegg; Susanne Muehlbauer; Dominik Heinzmann; Bert Lum; Sung-Bae Kim; Tadeusz Pienkowski; Mikhail Lichinitser; Vladimir Semiglazov; Bohuslav Melichar; Christian Jackisch

• Book ID: 119608967
• Publisher: The Lancet
• Year: 2012
• Tongue: English
• Weight: 245 KB
• Volume: 13
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/s1470-2045(12)70329-7